Truist Financial Issues Positive Forecast for Encompass Health (NYSE:EHC) Stock Price

Encompass Health (NYSE:EHC) had its price target boosted by research analysts at Truist Financial from $140.00 to $150.00 in a research note issued on Friday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 20.98% from the company’s previous close.

Several other analysts also recently weighed in on the stock. Leerink Partners set a $152.00 price objective on shares of Encompass Health in a research report on Friday, May 22nd. Wall Street Zen raised Encompass Health from a “hold” rating to a “buy” rating in a research report on Saturday, May 2nd. Weiss Ratings cut Encompass Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Friday, June 26th. Barclays raised their price objective on shares of Encompass Health from $140.00 to $144.00 and gave the company an “overweight” rating in a research report on Thursday. Finally, TD Cowen started coverage on shares of Encompass Health in a research note on Thursday, May 28th. They set a “buy” rating and a $125.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $145.86.

Encompass Health Trading Down 0.7%

NYSE:EHC opened at $123.99 on Friday. The stock has a fifty day moving average price of $106.52 and a 200 day moving average price of $104.44. The company has a current ratio of 1.17, a quick ratio of 1.17 and a debt-to-equity ratio of 0.76. Encompass Health has a 12-month low of $92.77 and a 12-month high of $127.99. The firm has a market cap of $12.30 billion, a PE ratio of 20.18, a price-to-earnings-growth ratio of 2.42 and a beta of 0.72.

Encompass Health (NYSE:EHC) last issued its earnings results on Wednesday, August 5th. The company reported $1.55 earnings per share for the quarter, beating the consensus estimate of $1.48 by $0.07. Encompass Health had a net margin of 10.01% and a return on equity of 18.34%. The firm had revenue of $1.60 billion for the quarter, compared to analysts’ expectations of $1.57 billion. During the same quarter last year, the company earned $1.40 earnings per share. The firm’s revenue was up 9.6% compared to the same quarter last year. Encompass Health has set its FY 2026 guidance at 6.020-6.250 EPS. Sell-side analysts anticipate that Encompass Health will post 5.96 earnings per share for the current fiscal year.

Insider Activity at Encompass Health

In related news, EVP Patrick William Tuer sold 682 shares of the company’s stock in a transaction that occurred on Monday, May 11th. The stock was sold at an average price of $104.56, for a total value of $71,309.92. Following the sale, the executive vice president owned 24,755 shares of the company’s stock, valued at approximately $2,588,382.80. This represents a 2.68% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 1.80% of the stock is owned by corporate insiders.

Institutional Trading of Encompass Health

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD boosted its position in Encompass Health by 24.6% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 4,805,413 shares of the company’s stock worth $510,047,000 after acquiring an additional 948,202 shares during the last quarter. Northwestern Mutual Wealth Management Co. increased its position in Encompass Health by 3,059,159.7% during the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 3,793,482 shares of the company’s stock worth $402,640,000 after purchasing an additional 3,793,358 shares during the last quarter. Wellington Management Group LLP raised its stake in Encompass Health by 21.7% during the fourth quarter. Wellington Management Group LLP now owns 3,384,877 shares of the company’s stock worth $359,271,000 after purchasing an additional 603,472 shares during the period. T. Rowe Price Investment Management Inc. boosted its holdings in shares of Encompass Health by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,722,887 shares of the company’s stock valued at $289,008,000 after purchasing an additional 581,812 shares during the last quarter. Finally, Alliancebernstein L.P. grew its stake in shares of Encompass Health by 6.8% during the 2nd quarter. Alliancebernstein L.P. now owns 2,039,314 shares of the company’s stock valued at $250,081,000 after buying an additional 129,276 shares during the period. Hedge funds and other institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation is a leading provider of post‐acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end‐of‐life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.